HEALTHYWAY INC (02587) rose more than 14% after issuing a positive profit alert. As of the time of writing, the stock was up 12.3%, trading at HK$5.04, with a turnover of HK$35.15 million. On February 12, the company announced that it expects to record revenue of no less than RMB 1.5 billion for the 2025 fiscal year, representing growth of at least 25% compared to the year ended December 31, 2024. Furthermore, the company anticipates a profit of no less than RMB 50 million for 2025, a significant turnaround from the net loss of RMB 269 million recorded in 2024. The company attributed this positive performance expectation primarily to the following factors: 1) Content service revenue increased from RMB 577 million in 2024 to no less than RMB 800 million in 2025. This growth stemmed from strategic adjustments made in response to market dynamics, such as resource integration and new service models. 2) Information technology service revenue grew from RMB 296 million in 2024 to no less than RMB 350 million in 2025. This was mainly driven by an increase in revenue from the group's big data technology services and the launch of its artificial intelligence (AI) software products. Notably, the group's self-developed AI software products, launched in 2025, contributed approximately RMB 30 million in revenue in their first year on the market. 3) Continuous improvement in operational efficiency. In 2024, total operating expenses (including administrative, selling, and research and development expenses) accounted for approximately 29% of revenue. This percentage decreased in 2025 despite business expansion.